LEGION-100 Study in mCRPC (SYNC-T Therapy SV-102)

Novel procedure combines image-guided tumor cryolysis with intratumoral immunotherapy infusion, with early clinical findings in metastatic prostate cancer

Las Vegas, Nevada (UroToday.com) -- Syncromune®, Inc., a clinical-stage biopharmaceutical company advancing SYNC-T™, an investigational platform combination immunotherapy for metastatic solid tumor cancers, today presented an oral presentation at the 2026 European Conference on Interventional Oncology (ECIO) in Basel, Switzerland. The oral presentation reflects continued clinical and scientific interest in the SYNC-T platform as development progresses. Read More

• Presentation highlights deep and durable responses and radiographic resolution of bone metastases in patients with advanced prostate cancer
• Final clinical data demonstrate an 87% overall response rate in patients with metastatic prostate cancer
• Results support recent advancement into LEGION-100 Phase 2a clinical trial

Las Vegas, Nevada (UroToday.com) -- Syncromune, Inc., a clinical-stage biopharmaceutical company dedicated to the development of SYNC-T, an in situ platform combination immunotherapy optimized for solid tumor cancers, Read More

Las Vegas, Nevada (UroToday.com) -- Syncromune®, Inc., a clinical-stage biopharmaceutical company dedicated to the development of SYNC-T, an in situ platform combination therapy optimized for solid tumor cancers, today announced the presentation of findings from its Phase 1 clinical study of SYNC-T Therapy SV-102 in patients with metastatic castration-resistant prostate cancer (mCRPC) and metastatic hormone-sensitive prostate cancer (mHSPC). The data, featured at the 26th Annual Meeting of the Society of Urological Oncology (SUO), highlight compelling responses among patients with bone metastases, a common and challenging manifestation of advanced prostate cancer. Read More

Las Vegas, Nevada (UroToday.com) -- Syncromune®, Inc., a clinical-stage biopharmaceutical company pioneering SYNC-T, an in situ personalized combination immunotherapy platform for solid tumor cancers, announced that an abstract has been accepted for presentation at the Society of Urologic Oncology (SUO) 26th Annual Meeting being held December 2-5, 2025 in Phoenix, Arizona. Read More

Reno, Nevada (UroToday.com) -- Syncromune® Inc., a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for solid tumor cancers, announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for SYNC-T SV-102 therapy, its lead candidate for the treatment of patients with metastatic castrate-resistant prostate cancer (mCRPC). SV-102 is part of Syncromune Inc.’s innovative SYNC-T platform, an in situ personalized therapy that uniquely employs a combination multi-target approach to cancer treatment, aiming to improve outcomes and quality of life for patients. Read More